{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:48:33Z","timestamp":1789876113440,"version":"4.0.1"},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,2,21]],"date-time":"2008-02-21T00:00:00Z","timestamp":1203552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:p>Human invariant V\u03b124 natural killer T (NKT) cells are a novel, distinct lymphocyte population, characterized by an invariant T\u2010cell receptor V\u03b124 chain paired with V\u03b211. V\u03b124 NKT cells are activated by a specific glicolipid ligand, \u03b1\u2010GalCer, and rapidly produce a large amount of Th1 and Th2 cytokines, thereby modulating other immune cells such as antigen\u2010specific CD4 and CD8 T cells, NK cells, and dendritic cells. Recent studies have shown that NKT cells play pivotal regulatory roles in many immune responses, including antitumor immunity. We herein review the quantitative alteration and functional deterioration of circulating V\u03b124 NKT cells in various cancer\u2010bearing patients. We also summarize the recent progress in the clinical studies of NKT cell\u2010based tumor immunotherapy. Novel immunological results including the increased peripheral blood V\u03b124 NKT cells and IFN\u2010producing cells after the immunotherapy were revealed. The details of the safety profile and the antitumor responses were also disclosed. Although the objective clinical responses still remain unclear, some encouraging results have emerged. Therefore, NKT cell\u2010based immunotherapy may potentially be an effective strategy for the treatment of cancer patients. (Cancer Sci 2008; 99: 638\u2013645)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2008.00730.x","type":"journal-article","created":{"date-parts":[[2008,2,22]],"date-time":"2008-02-22T00:13:19Z","timestamp":1203639199000},"page":"638-645","source":"Crossref","is-referenced-by-count":67,"title":["Clinical applications of natural killer T cell\u2013based immunotherapy for cancer"],"prefix":"10.1111","volume":"99","author":[{"given":"Shinichiro","family":"Motohashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,2,21]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141057"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.297"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104608"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5343.1626"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.8.1521"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.8.1529"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1028"},{"key":"e_1_2_9_9_2","first-page":"5102","article-title":"Antitumor cytotoxicity mediated by ligand\u2010activated human V\u03b124 NKT cells","volume":"59","author":"Kawano T","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011786"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.7.2067"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(02)00497-0"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503366102"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.9.4647"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1259"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030324"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040317"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200106)31:6<1720::AID-IMMU1720>3.0.CO;2-U"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1203-1164"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.6.3114"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2004.03.003"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.10.5690"},{"key":"e_1_2_9_23_2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4049\/jimmunol.163.5.2387","article-title":"Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with \u03b1\u2010galactosylceramide","volume":"163","author":"Toura I","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2002.tb01270.x"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10678"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20998"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2004.09.003"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.7.4046"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.6494"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20050"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04465.x"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021650"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0877"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031462"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0114"},{"key":"e_1_2_9_36_2","first-page":"3702","article-title":"A phase I study of the natural killer T\u2010cell ligand \u03b1\u2010galactosylceramide (KRN7000) in patients with solid tumors","volume":"8","author":"Giaccone G","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni827"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1453"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21197"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.00217.x"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1155"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042592"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.10.5140"},{"key":"e_1_2_9_44_2","doi-asserted-by":"crossref","unstructured":"UchidaT HoriguchiS TanakaYet\u00a0al.Phase I study of \u03b1\u2010galactosylceramide\u2010pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.Cancer Immunol Immunother2007;57:337\u201345.","DOI":"10.1007\/s00262-007-0373-5"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-007-9112-0"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2003.12.003"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011908"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.7.3140"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00529.x"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0941"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2008.00730.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2008.00730.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T23:31:44Z","timestamp":1697239904000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2008.00730.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,21]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1349-7006.2008.00730.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00730.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,21]]}}}